McDonald's is navigating significant business challenges as GLP-1 receptor agonist medications like Ozempic reshape consumer eating patterns. The fast-food giant, long associated with indulgent portions and calorie-dense offerings, is strategically diversifying its menu to appeal to health-conscious customers pursuing weight management. This pivot reflects broader industry transformation as pharmaceutical innovations influence dietary choices and force major restaurant chains to reconsider their traditional product positioning and marketing approaches.

Summary auto-generated by AI from the original publisher's content. Editorial standards.